What is Vivo Bio Tech Ltd (511509) share price return in the past 10 years?

Vivo Bio Tech Ltd share price has declined -3.8% annually (CAGR) over the past ten years.

What is the share price of Vivo Bio Tech Ltd (511509)?

Company share prices are keep on changing according to the market conditions. The current trading price of Vivo Bio Tech Ltd (511509) on 30-Apr-2026 16:59:59 at 16:59 is 27.87.

What is the P/E ratio of Vivo Bio Tech?

The latest standalone P/E ratio of Vivo Bio Tech as of 30-Apr-2026 is 13.20.

What is the P/B ratio of Vivo Bio Tech Ltd (511509)?

The latest standalone P/B ratio of Vivo Bio Tech Ltd (511509) as of 30-Apr-2026 is 0.64.

What is the 52-week high and low of Vivo Bio Tech Ltd (511509)?

The 52-week high of Vivo Bio Tech Ltd (511509) is Rs. 43.35 and the 52-week low is Rs. 20.35.

Vivo Bio Tech Ltd (511509) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Vivo Bio Tech Ltd (511509)
Brand: Vivo Bio Tech

Key Metrics

Market Cap

₹62 Cr.

P/E Ratio

13.20

Price to Book (P/B)

0.64

Price to Sales (P/S)

1.21

EV/EBITDA

4.85

Return on Capital Employed (ROCE)

13.06%

Current Price

₹27.9

Return on Equity (ROE)

12.13%

Return on Assets (ROA)

5.48%

Operating Profit Margin

44.7%

Net Profit Margin

16.22%

Gross Profit Margin

38.8%

Book Value per Share

₹43.6

Sales Growth (YoY)

3.99%

Sales Growth (3 Years)

-3.16%

Operating Profit Growth (1 Year)

-1.93%

Operating Profit Growth (3 Years)

9.01%

Net Profit Growth (1 Year)

200.4%

52-Week Low / High

₹20 / 43

Net Profit Growth (3 Years)

50.9%

Dividend Yield

0.00%

Promoter Holding

35.43%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Stock return of Vivo Bio Tech Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -3.8% based on the current price.

Q.1 Revenue growth of Vivo Bio Tech Ltd?

Vivo Bio Tech Ltd revenue growth is 4% for FY-2025, which is above its 5-year CAGR of -3.35%, indicating faster growth.

Q.1 Which industry/sub-sector does Vivo Bio Tech Ltd belong to?

Vivo Bio Tech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Promoter shareholding and pledge status of Vivo Bio Tech Ltd?

Promoters hold 35.43% of the Vivo Bio Tech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Vivo Bio Tech Ltd vs industry peers?

Vivo Bio Tech Ltd revenue CAGR is -3.35%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

DeciZen - make an informed investing decision on Vivo Bio Tech

Based on:

Data

M-Cap below 100cr DeciZen not available

Vivo Bio Tech stock performance

Key Ratios

Is Vivo Bio Tech Ltd an attractive stock to invest in?

1. Is Vivo Bio Tech Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Vivo Bio Tech Ltd is a average quality company.

2. Is Vivo Bio Tech Ltd undervalued or overvalued?

The key valuation ratios of Vivo Bio Tech Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Vivo Bio Tech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vivo Bio Tech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	6%	12.4%	15.2%	9.6%	14.2%	19.5%	9.6%	11.3%	10.2%	13.1%	-
Value Creation Index ⓘ	-0.6	-0.1	0.1	-0.3	0.0	0.4	-0.3	-0.2	-0.3	-0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	28.6	34.1	47	55.8	55.4	51.8	51.4	51.6	44.9	46.7	51
Sales YoY Gr.	-	19.4%	37.7%	18.8%	-0.9%	-6.5%	-0.8%	0.5%	-13.1%	4%	-
Adj EPS ⓘ	1	2.7	3.2	1.9	3.5	4.2	1.6	1.8	1.7	2.5	2.1
YoY Gr.	-	173.5%	19%	-41.4%	85.6%	21.6%	-62.3%	11.3%	-4%	48.8%	-
BVPS (₹) ⓘ	10.7	13.5	17.5	21.8	25.6	30.6	32.3	34.5	36.3	41.2	43.6
Adj Net Profit ⓘ	0.9	2.5	3.1	2.3	4.5	5.7	2.3	2.6	2.5	4.3	5
Cash Flow from Ops. ⓘ	8.7	-5.7	11.1	-0.8	7.7	14.1	16.4	14.7	15.8	11.8	-
Debt/CF from Ops. ⓘ	1.9	-4.8	2.3	-27.5	2.9	2	4	4.1	4.5	4.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5.6%	-3.4%	-3.2%	4%
Adj EPS ⓘ	11.1%	-6.1%	16.8%	48.8%
BVPSⓘ	16.1%	10%	8.5%	13.5%
Share Price	-3.8%	-14.7%	3.7%	-25.3%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	9.5	22.1	19.7	9.9	14.8	15	5.1	5.3	4.8	6.6	5
Op. Profit Mgn % ⓘ	13	22.4	23.2	17.2	22.6	34.4	31.5	42.3	47.4	44.7	42.2
Net Profit Mgn % ⓘ	3.2	7.3	6.7	4.1	8.1	11	4.4	5.1	5.7	9.3	9.2
Debt to Equity ⓘ	1.7	2.2	1.5	0.8	0.7	0.7	1.4	1.2	1.3	0.7	-
Working Cap Days ⓘ	138	155	165	158	170	191	188	204	320	348	188
Cash Conv. Cycle ⓘ	-45	-11	37	53	81	118	127	131	152	140	87

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 16.75%

Debt to equity has declined versus last 3 years average to 0.73

Sales growth is good in last 4 quarters at 11.67%

Return on Equity has declined versus last 3 years average to 5.00%

Sales growth has been subdued in last 3 years -3.16%

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	2.1	2
TTM Sales (₹ Cr.)	51.1	51.4
BVPS (₹) ⓘ	43.6	43.5
Reserves (₹ Cr.) ⓘ	75	75
P/BV ⓘ	0.64	0.64
PE ⓘ	13.20	13.69

From the Market
52 Week Low / High (₹)	20.35 / 43.35
All Time Low / High (₹)	1.10 / 115.10
Market Cap (₹ Cr.)	61.9
Equity (₹ Cr.)	22.2
Face Value (₹)	10
Industry PE ⓘ	43.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Vivo Bio Tech - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	28.58	34.13	47	55.83	55.35	51.78	51.39	51.62	44.88	46.67
Operating Expenses ⓘ +	24.88	26.50	36.12	46.32	42.88	33.97	35.30	29.80	23.63	25.83
Manufacturing Costs	2.55	3.12	3.10	5.07	6.89	5.87	3.77	4.56	4.24	3.60
Material Costs	8.80	8.14	9.57	11.76	8.56	7.21	11.44	6.77	3.85	5.79
Employee Cost	4.34	5.50	7.66	9.58	10	8.57	9.42	13.15	10.13	11.86
Other Costs ⓘ	9.18	9.74	15.80	19.91	17.43	12.32	10.67	5.32	5.41	4.58
Operating Profit ⓘ	3.71	7.63	10.88	9.51	12.47	17.81	16.09	21.82	21.25	20.84
Operating Profit Margin (%)	13.0%	22.4%	23.2%	17.0%	22.5%	34.4%	31.3%	42.3%	47.4%	44.7%
Other Income ⓘ +	0.89	0.40	0.13	0.01	0.05	0.08	0.09	0.04	0.04	4.80
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.47	1.29	2.37	2.64	3.10	3.67	4.27	7.99	7.95	7.55
Depreciation ⓘ	3.35	3.90	4.64	5.06	5.17	5.59	7.44	9.27	9.29	9.02
Profit Before Tax ⓘ	0.78	2.84	4.01	1.83	4.26	8.62	4.47	4.61	4.05	9.08
Tax ⓘ	-0.13	0.33	0.88	-0.42	-0.19	2.94	2.27	1.97	1.53	1.51
Profit After Tax	0.91	2.50	3.12	2.25	4.44	5.68	2.20	2.63	2.52	7.57
PAT Margin (%)	3.2%	7.3%	6.6%	4.0%	8.0%	11.0%	4.3%	5.1%	5.6%	16.2%
Adjusted EPS (₹)	1.0	2.7	3.2	1.8	3.5	4.2	1.5	1.8	1.7	4.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	10.08	12.60	17.23	26.98	33.04	41.12	46.46	51.87	54.40	70.92
Share Capital ⓘ	9.35	9.35	9.85	12.35	12.89	13.42	14.26	14.90	14.90	17.16
Reserves ⓘ	0.73	3.25	7.38	14.63	20.15	27.70	32.19	36.97	39.49	53.75
Debt +	16.91	27.06	25.11	21.67	22.09	24.35	58.80	52.45	62.24	44.07
Long Term Debt	14.11	20.93	13.90	8.90	7.41	12.42	47.88	40.87	39.56	32.71
Short Term Debt	2.81	6.12	11.21	12.77	14.67	11.92	10.92	11.59	22.68	11.36
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	8.75	5.40	7.98	3.87	3.91	1.39	2.32	0.94	1.06	0.98
Others Liabilities ⓘ	9.93	6.08	9.20	2.56	0.84	10.46	12.73	15.54	17.10	25.32
Total Liabilities ⓘ	45.67	51.14	59.53	55.08	59.87	77.31	120.30	120.81	134.80	141.29
Fixed Assets
Net Fixed Assets ⓘ +	23.35	28.37	27.47	29.82	31.63	48.69	91.81	85.51	77.01	84.88
Gross Block	34.95	43.88	47.61	55.02	62	84.65	135.16	138.12	138.70	155.53
Accumulated Depreciation	11.60	15.51	20.14	25.20	30.37	35.97	43.35	52.61	61.69	70.65
CWIP ⓘ	0.04	2.96	3.94	0.07	0.15	0.32	0.87	1.90	9.21	12.84
Investments ⓘ	0.03	0.03	0.03	0.03	0.04	0.04	0.04	0.04	0.04	0.04
Inventories	4.08	4.56	7.59	8.24	10.58	13.28	9.81	7.97	8.77	7.79
Trade Receivables	3.82	7.67	11.78	8.41	10.48	7.29	12.02	12.38	11.37	11.21
Cash Equivalents	11.85	1.18	4.15	0.53	0.99	1.10	1.47	0.99	1.32	1.21
Others Assets ⓘ	2.50	6.36	4.58	7.99	6	6.59	4.28	12.01	27.08	23.32
Total Assets ⓘ	45.67	51.14	59.53	55.08	59.87	77.31	120.30	120.81	134.80	141.29

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	8.73	-5.65	11.11	-0.79	7.72	14.10	16.43	14.73	15.83	11.83
PBT ⓘ	0.78	2.85	4.01	1.83	4.26	8.62	4.47	4.61	4.05	9.08
Adjustment ⓘ	3.82	5.19	7.02	7.70	8.27	9.12	11.43	16.92	17.07	11.91
Changes in Working Capital ⓘ	4.47	-12.07	3.34	-8.1	-1.9	2.82	3.98	-3.46	-2.24	-5.04
Tax Paid ⓘ	0.13	-0.33	-0.88	0.42	0.19	-2.94	-2.27	-1.97	-1.53	-2.08
Cash Flow From Investing Activity ⓘ +	-7.12	-11.84	-4.72	-3.53	-7.08	-22.82	-51.11	-4	-7.95	-15.84
Capex	-7.11	-11.84	-4.72	-3.53	-7.07	-22.82	-51.11	-4	-7.95	-15.84
Net Investments	-0.01	0	0	0	-0.01	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	-0.32	6.83	-3.43	0.70	-0.18	8.83	35.04	-11.20	-7.56	3.90
Net Proceeds from Shares ⓘ	0	0	1.50	5.70	1.31	3.82	2.40	2.10	0	16.22
Net Proceeds from Borrowing ⓘ	-0.32	6.83	-4.93	-5	-1.49	5.01	35.45	-7.01	-1.30	-6.85
Interest Paid ⓘ	0	0	0	0	0	0	-2.81	-6.28	-6.25	-5.47
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	-0	0	0	0
Net Cash Flow ⓘ	1.29	-10.67	2.96	-3.62	0.46	0.11	0.37	-0.47	0.32	-0.11

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	9.48	22.14	20.98	10.21	14.85	15.35	5.06	5.41	4.78	12.13
ROCE (%)	5.96	12.39	15.17	9.58	14.15	19.47	9.55	11.26	10.15	13.06
Asset Turnover Ratio	0.66	0.71	0.85	0.97	0.96	0.75	0.52	0.43	0.35	0.34
PAT to CFO Conversion(x)	9.59	-2.26	3.56	-0.35	1.74	2.48	7.47	5.6	6.28	1.56
Working Capital Days
Receivable Days	51.90	61.40	75.50	66	62.30	62.70	68.60	86.30	96.60	88.30
Inventory Days	56	46.20	47.20	51.70	62	84.10	82	62.90	68.10	64.80
Payable Days	323.60	317	255.20	183.90	166	134.30	59.10	87.80	94.90	64.30

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vivo Bio Tech Ltd FAQs

The current trading price of Vivo Bio Tech on 30-Apr-2026 16:59 is ₹27.87.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Apr-2026 the market cap of Vivo Bio Tech stood at ₹61.85 Cr

The latest P/E ratio of Vivo Bio Tech as of 29-Apr-2026 is 13.20.

The latest P/B ratio of Vivo Bio Tech as of 29-Apr-2026 is 0.64.

The 52-week high of Vivo Bio Tech is ₹43.35 and the 52-week low is ₹20.35.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vivo Bio Tech is ₹51.09 ( Cr.) .

About Vivo Bio Tech Ltd

Vivo Bio Tech was incorporated on February 12, 1987 as Golden Growth Fund, Hyderabad-based Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities. The company was converted into a public limited company from Jun. 19, 1992. VBTL provides services ranging from insilico design, wet lab contract research, preclinical research and clinical studies spanning the entire drug discovery value chain.

It is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of custom research, In-vitro and In-vivo toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Our experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. Tailored and dedicated to our clients, we distinguish your development plan is as superlative as the products you bring to our testing facilities.

The Custom Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Our scientists will team up with you to develop solution for the most difficult to deal products including purification of untagged & poorly expressed proteins.

In-vitro Services offers solutions for pharmacologic, toxicological & bioanalytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by our scientists.

Vivo Bio Tech has obtained permission from the Govt. of India for developing Biotech Sector Specific 'Special Economic Zone' at its site (39 acres) in Pregnapur, Gajwel Mandal, Medak District, Andhra Pradesh.The Vivo Bio Tech SEZ is located adjacent to Karimnagar highway road (approx 16 km from ICICI Knowledge Park and SP Biotech Park). The site is approximately 53km from Secunderabad Railway Station and around 90km from the new airport (Shamshabad).

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Vivo Bio Tech Ltd (511509) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Vivo Bio Tech Share Price